New hope for Hard-to-Treat colorectal cancer: immunotherapy before liver surgery
NCT ID NCT07277322
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study tests whether giving immunotherapy before surgery can help people with a common type of colorectal cancer (MSS) that has spread to the liver. About 24 participants will receive the drug dupilumab before their liver surgery. The goal is to see if this approach is safe and can shrink the tumors, making surgery more effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- A new test could reveal how radiation affects the liver
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- A new clue in the fight against colorectal cancer recurrence?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?